ImmuPharma reports positive financial and business update

LONDON: ImmuPharma PLC, a specialist drug discovery and development company, has announced a positive and comprehensive update on its financial situation and its portfolio of products. The company, which is listed on the London Stock Exchange’s AIM market, said it has enough funds for its immediate needs and does not plan to raise more equity…

ImmuPharma signs collaboration with Imperial College London

LONDON, UK: ImmuPharma Plc, the specialist drug discovery and development company, has signed a 2-year collaboration agreement with Imperial College London. Under the collaboration, Imperial College will provide significant intellectual input and guidance on a number of innovative peptide assets being developed at the R&D subsidiary, ImmuPharma Biotech in Bordeaux. Dr Tim Franklin, Chief Operating…